AstraZeneca’s KRAS deal with Yusen Jianheng; Abeona gets a PDUFA date

As­traZeneca part­ners with Chi­nese biotech: Yusen Jian­heng Bio­phar­ma­ceu­ti­cal said last week that As­traZeneca will help de­vel­op and com­mer­cial­ize a pre­clin­i­cal small mol­e­cule that tar­gets the KRAS G12D mu­ta­tion. Per the deal, As­traZeneca will pay $24 mil­lion up­front, with mile­stones worth up to $395 mil­lion.

Abeona’s cell ther­a­py grant­ed pri­or­i­ty re­view: The com­pa­ny an­nounced Mon­day that the FDA is set to de­cide whether to ap­prove pradema­gene za­mik­er­a­cel, or pz-cel, by May 25, and the reg­u­la­tor does not plan to hold an ad­vi­so­ry com­mit­tee meet­ing. The ther­a­py is be­ing con­sid­ered for pa­tients with re­ces­sive dy­s­troph­ic epi­der­mol­y­sis bul­losa, a rare dis­ease that caus­es the skin to blis­ter. Its stock $ABEO was up about 13% on Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.